Piershale Financial Group, Inc. Brainstorm Cell Therapeutics Inc. Transaction History
Piershale Financial Group, Inc.
- $157 Million
- Q2 2023
A detailed history of Piershale Financial Group, Inc. transactions in Brainstorm Cell Therapeutics Inc. stock. As of the latest transaction made, Piershale Financial Group, Inc. holds 100 shares of BCLI stock, worth $175. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100
Previous 100
-0.0%
Holding current value
$175
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding BCLI
# of Institutions
29Shares Held
8.63MCall Options Held
160KPut Options Held
30.5K-
Armistice Capital, LLC New York, NY6.9MShares$12.1 Million0.03% of portfolio
-
Black Rock Inc. New York, NY386KShares$676,2240.0% of portfolio
-
State Street Corp Boston, MA117KShares$205,2050.0% of portfolio
-
Northern Trust Corp Chicago, IL112KShares$196,6260.0% of portfolio
-
Raymond James & Associates St Petersburg, FL95.2KShares$166,5170.0% of portfolio
About BRAINSTORM CELL THERAPEUTICS INC.
- Ticker BCLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,486,200
- Market Cap $63.9M
- Description
- Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...